Use of rituximab to treat pemphigus
CA 2944644 C · Owner: Biogen Inc. · Inventors: Kunkel, Lori A.; Curd, John G.; Grillo-Lopez, Antonio J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
There is disclosed the use of rituximab in combination with a glucocorticostcroid for treating pemphigus in a human. The glucocorticosteroid is for use concurrently or for use in either order with the rituximab. Preferably the glucocorticosteroid is prednisone, rnethylprednisolone dexamethasone or any mixture thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 4, 2000 and granted August 22, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 4, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 4, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.